-
PLGA Microspheres for Controlled Cartilage Corticosteroids
2026-09-10
The 2026 Pharmaceutics study shows that PLGA microsphere size, surface chemistry, and drug stability jointly govern corticosteroid transport and release in articular cartilage. Its bovine explant, HPLC, and ester-hydrolysis analyses provide a practical framework for designing more predictable intra-articular delivery systems for osteoarthritis research.
-
MDM1, p53, and Chemoradiotherapy Sensitivity in CRC
2026-09-10
A 2025 Cancer Biology & Medicine study identifies MDM1 as a candidate biomarker and mechanistic regulator of chemoradiotherapy response in colorectal cancer. Its experiments connect MDM1 overexpression with reduced YBX1 occupancy at the TP53 promoter, increased p53 expression, and enhanced apoptosis, providing a framework for studying treatment resistance.
-
IWR-1-endo: A Wnt Signaling Inhibitor Workflow
2026-09-09
IWR-1-endo provides a practical way to suppress Wnt/β-catenin activity while connecting pathway measurements with proliferation, regeneration, and high-content morphology assays. This workflow combines product-specific handling guidance with assay-design lessons from a cardiomyocyte profiling study, helping researchers improve dose selection, imaging quality, and mechanistic interpretation.
-
Sulfamonomethoxine Toxicity Across Aquatic Trophic Levels
2026-09-09
This study established a comparative toxicity profile for sulfamonomethoxine across algae, cladocerans, and fish-relevant aquatic testing, combining short-term and chronic endpoints. Its central finding was that microalgae were more sensitive than cladocerans, highlighting the importance of trophic-level selection when evaluating antibiotic residues in aquaculture-impacted waters.
-
Bifendate (DDB): A Systems-Level Assay Guide
2026-09-08
Bifendate (DDB) is a hepatoprotective research compound whose lipid, autophagy, and multiomics effects require carefully matched endpoints. This guide translates its molecular profile into practical assay decisions while distinguishing mechanistic evidence from translational limitations.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-09-08
Hao et al. developed ICG-loaded zirconium MOF nanoparticles functionalized with the PD-1/PD-L1 blocking polypeptide AUNP12 through a disulfide-linked, copper-free click chemistry strategy. The platform couples glutathione-responsive immunomodulator release with near-infrared photothermal therapy, offering a mechanistic approach for improving tumor-cell killing and immune activation beyond single photothermal treatment.
-
BMS-777607: c-Met Inhibitor Workflow Guide
2026-09-07
BMS-777607 supports precise MET signaling pathway inhibition in cancer metastasis models and can also serve as an exploratory perturbation in megakaryocyte maturation assays. This guide connects validated c-Met pharmacology with optimized hiPSC-derived platelet workflows while separating established evidence from practical assay recommendations.
-
DOPE Workflows for Delivery and Lipid-Death Assays
2026-09-07
DOPE combines acid-responsive membrane fusion with a practical role in nucleic acid delivery, making it useful for liposome, LNP, and transfection workflows. This guide also shows how to use DOPE carefully in Magnaporthe oryzae conidial-death assays without confusing a lipid-rescue phenotype with proof of a direct ferroptosis mechanism.
-
HyperScribe All in One mRNA Synthesis Kit Workflow
2026-09-05
Build translation-ready, ARCA-capped and polyadenylated transcripts for vaccine, translation, antisense, and RNAi studies with one integrated workflow. This guide separates product-supported specifications from recommended starting conditions and shows how to troubleshoot yield, integrity, and expression problems.
-
MAPK10–KRT16 Axis in NSCLC Metastasis
2026-09-04
The reference study identifies MAPK10 as a metastasis-suppressive kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. Cellular, animal, and clinical data support the MAPK10/KRT16/RNF213 axis as a mechanistic framework for understanding NSCLC dissemination and developing prognostic biomarkers, although further validation is needed.
-
Autophagy and Resveratrol-Induced Apoptosis in RCC
2026-09-04
Yao, Fan, and He showed that resveratrol induces ROS-associated mitochondrial damage and caspase-3-dependent apoptosis in renal cell carcinoma 786-O cells, while simultaneously activating JNK-linked autophagy. The study’s central insight is that autophagy functions as a protective response, suggesting that combining resveratrol with autophagy inhibition may intensify tumor-cell death, although validation beyond this in vitro model is needed.
-
Dextrose (D-glucose) as a Metabolic Assay Variable
2026-09-03
Dextrose (D-glucose) is more than a routine nutrient: it is a controllable variable for studying hypoxia, metabolic competition, and immune-cell function. This guide translates recent tumor immunometabolism insights into rigorous assay-design decisions and practical handling recommendations.
-
ABT-199: Selective BCL-2 Inhibitor Assays
2026-09-03
A scenario-based guide to using ABT-199 (GDC-0199), Bcl-2 inhibitor, potent and selective (SKU A8194) in viability, cytotoxicity, and apoptosis assays. It connects mechanism, dose design, solvent control, data interpretation, and practical product-selection criteria for reproducible hematologic research.
-
Carbohydrate-Decorated Nanoparticles for Macrophages
2026-09-02
Chen and colleagues developed biodegradable nanoparticles that combine a cationic lipid-like component with carbohydrate-decorated PLGA or PLGA-PEG to improve macrophage uptake and gene delivery. Mannose and dextran produced particularly informative targeting and mRNA-transfection responses, supporting carbohydrate presentation as a tunable variable rather than a generic surface modification.
-
CDK4/6–BET Synergy in Pancreatic Cancer
2026-09-02
Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 suppresses pancreatic ductal adenocarcinoma more effectively than either agent alone. The study links this effect to GSK3β-mediated Wnt/β-catenin regulation and reversal of the epithelial-to-mesenchymal transition, while highlighting a metastasis-related liability of CDK4/6 monotherapy.